| Literature DB >> 26660529 |
P Vemer1,2, I Corro Ramos3, G A K van Voorn4, M J Al3, T L Feenstra5,6.
Abstract
BACKGROUND: A trade-off exists between building confidence in health-economic (HE) decision models and the use of scarce resources. We aimed to create a practical tool providing model users with a structured view into the validation status of HE decision models, to address this trade-off.Entities:
Mesh:
Year: 2016 PMID: 26660529 PMCID: PMC4796331 DOI: 10.1007/s40273-015-0327-2
Source DB: PubMed Journal: Pharmacoeconomics ISSN: 1170-7690 Impact factor: 4.981
Source of contact information of health-economic experts
| Source | Number of experts contacted |
|---|---|
| Personal network of the project team | 129 |
| Proposed replacements by invitees | 10 |
| Involved in the ISPOR-SMDM Good Modeling Practices Task Force | 31 |
| Authors of the CHEERS statement [ | 6 |
| Involved in the organizing committee of at least one of the ISPOR conferences (International, European, Asia–Pacific, and Latin America) between 2008 and 2014 | 140 |
| Involved in the ISPOR regional chapters | 100 |
| Identified by other experts | 19 |
| Identified by biomedexperts.com as experts in “Economic Models” and/or “Markov Chains” | 35 |
CHEERS Consolidated Health Economic Evaluation Reporting Standards, ISPOR International Society For Pharmacoeconomics and Outcomes Research, SMDM Society for Medical Decision making
Fig. 1Building the validation-assessment tool. Grey boxes display work by the project team; white boxes display input from outside sources. 1High non-response since the invitations were sent out to a very wide range of people with the aim of selecting a suitable panel; see Table 1. AdViSHE Assessment of the Validation Status of Health-Economic decision models
Fig. 2Typology of validation techniques, based on [4]
Background information of participants who answered during at least one of the five Delphi rounds
| Participant characteristics | Number (%) |
|---|---|
| Total number of individuals who answered in at least one round | 47 (100) |
| Geographical region [ | |
| Western Europe | 28 (60) |
| Southern Europe | 5 (11) |
| Northern Europe | 4 (9) |
| Eastern Europe | 3 (7) |
| North America | 2 (4) |
| Central America | 2 (4) |
| South America | 1 (2) |
| Southern Asia | 1 (2) |
| Australia and New Zealand | 1 (2) |
| Field of work | |
| Academics | 25 (53) |
| Consulting | 8 (17) |
| Pharmaceutical industry | 8 (17) |
| Government, decision making | 6 (13) |
| Number of responses | |
| Provided comments three times or more | 24 (50) |
| Provided comments twice | 12 (26) |
| Provided comments once | 12 (26) |
Fig. 3HE expert questions. AdViSHE Assessment of the Validation Status of Health-Economic decision models, HE health-economic. 1 ISPOR International Society For Pharmacoeconomics and Outcomes Research
Fig. 4AdViSHE: Assessment of the Validation Status of Health-Economic decision models. 1 ISPOR International Society For Pharmacoeconomics and Outcomes Research, SMDM Society for Medical Decision making, CHEERS Consolidated Health Economic Evaluation Reporting Standards
| Model users can accept health-economic (HE) decision models as valid without further examination, thereby reducing model confidence, or they can validate models themselves, implying overlap with the validation efforts of the modelling team. Existing modelling and validation guidelines give little guidance in setting priorities for validation, nor do they address the issue of overlapping work by model developers and users. |
| Assessment of the Validation Status of Health-Economic decision models (AdViSHE) allows model developers to provide model users with structured information regarding the validation status of their HE decision model. Its main purpose is to avoid some of the current overlap in validation efforts and provide information on a list of priority validation items, selected by a Delphi consensus process. AdViSHE can be used to reproduce stated results and guide complementary validation efforts, which is expected to increase model users’ understanding of, and confidence in, the model and its outcomes. |